Do Allergy Shots Wear Off? Post-Treatment Durability Explained

Research suggests that allergy shot benefits persist for 3 to 12 years after completing a full treatment course in most patients. The landmark Durham et al. study in the New England Journal of Medicine (1999) showed that grass pollen SCIT benefits were maintained for at least 3 years after stopping a 3- to 4-year course. A 12-year follow-up by Eng et al. (Allergy 2006) found that treated patients still significantly outperformed untreated controls over a decade later, even though skin-test reactivity had partially returned toward baseline. The key qualifier is 'full course' — patients who stopped early showed substantially less durable benefit.

Yes, stopping allergy shots before completing the recommended 3- to 5-year course significantly increases the risk that benefits will not be durable. Research by Marogna et al. in Clinical and Experimental Allergy (2010) found that shorter treatment courses — particularly those under 3 years — were associated with substantially higher relapse rates compared to full 3- to 5-year courses. The immune system requires sustained exposure to allergen at maintenance doses to fully establish long-term tolerance. Stopping during the build-up phase or early maintenance typically means that any improvement achieved during treatment is unlikely to be sustained long term.

Several factors predict higher relapse risk after stopping allergy shots. Patients sensitized to multiple allergens (polysensitized) relapse faster than those treated for a single allergen, as shown by Jacobsen et al. (Allergy 2007). Shorter treatment duration — particularly courses under 3 years — correlates with higher relapse rates. Younger age at treatment completion and less severe initial sensitization tend to predict better durability. Adults with longer-standing allergic disease may also relapse more readily. Your allergist should assess these individual factors when discussing whether to stop treatment or extend for an additional season.

Allergy relapse after completing SCIT is not a treatment failure — it is a recognized outcome for the roughly 25% of patients whose immunity does not sustain long-term. Good news: patients who relapse can restart allergy shots, and they typically respond faster the second time. Per Cox et al. (JACI 2011), retreatment after relapse usually allows an accelerated build-up schedule because the immune system retains some memory from the initial course. You should contact your allergist at the first sign of symptom return — early retreatment typically produces better outcomes than waiting until symptoms become severe again.

Yes, evidence suggests durability differs by allergen type. Grass pollen SCIT has the strongest long-term durability evidence, with multiple trials showing benefits persisting 3 to 12 years post-treatment. Dust mite SCIT also shows strong long-term data, including a study by Rodriguez-Plata showing 55% of patients asymptomatic at 10 years post-treatment. Cat and mold SCIT have somewhat weaker long-term data. The strongest predictor of durability across all allergens remains whether the full recommended treatment course was completed, regardless of the specific allergen being targeted.

Not necessarily — and this is one of SCIT's most important features. Research shows that clinical tolerance can persist even as some immunologic markers, like skin test reactivity, partially return toward baseline. Eng et al. (Allergy 2006) found that at 12-year follow-up, skin test reactivity in former SCIT patients had returned to near-baseline levels, yet clinical symptoms remained significantly lower than untreated controls. This suggests that durable tolerance involves immune memory mechanisms beyond IgE levels alone. Disease modification — such as prevention of new allergen sensitizations and reduced asthma development — appears to be particularly durable even as some serologic markers wane.

Allergy shot benefits do not disappear suddenly — they tend to wane gradually if relapse occurs, typically over months rather than days. Signs of waning protection include increasing nasal or eye symptoms during pollen season, needing to restart medications you had previously stopped, and allergy symptoms returning during exposures that had become well-tolerated. Your allergist can also perform follow-up skin tests or specific IgE blood tests to assess whether your allergen reactivity has increased. The AAAAI/ACAAI Practice Parameter recommends reassessing patients approximately one year after stopping treatment to identify early relapse and discuss retreatment options.